Sorrento Therapeutics, Inc. (OTC.BB: SRNE) has constructed an extensive library of full-length, full human monoclonal antibodies (mAbs). Initial analysis indicates a potential diversity of over 1 trillion unique mAbs.
Xplosive Stocks, an online financial publication, provides investors timely stock market information.
Sign Up Today for our Free Stock Newsletter
The company believes that this makes it the largest full-length, fully human antibody library available for drug discovery and development partnerships. Sorrento’s proprietary technologies generate antibodies which are encumbered by 3rd-part royalty obligations placed on convention antibody discovery technologies.
Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease.
Sign up for the free Xplosive Stocks newsletter. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by Xplosive Stocks can sign up for free by visiting our website.
About Us
Xplosive Stock is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We focus on Xplosive Stocks and track small cap companies that are on the brink of a financial breakout. To feature a company on our website please contact us at the email listed below.
Please click here to read the full disclaimer.
